Clinical Trial Update: Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath [Phase 2]

View source ↗

Summary

Phase 2 update on non-myeloablative allogeneic stem cell transplantation using mis-matched family donor cells purged with Campath (alemtuzumab).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Solid Tumors

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)

Snippet

Sponsor: David Rizzieri, MD | Conditions: Lymphoma, Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2014-06-03